DDInter927 DDInter1085
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Lomitapide {u} (Compound) resembles {v} (Compound) Antrafenine
Lomitapide {u} (Compound) binds {v} (Gene) CYP3A4
Lomitapide {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Lomitapide {u} (Compound) causes {v} (Side Effect) Xanthoma
Lomitapide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Terbinafine
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Lomitapide {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fexofenadine
Lomitapide (Compound) resembles Antrafenine (Compound)
Lomitapide (Compound) binds CYP3A4 (Gene)
Lomitapide (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Lomitapide (Compound) causes Xanthoma (Side Effect)
Lomitapide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lomitapide may lead to a major life threatening interaction when taken with Terbinafine
Lomitapide may lead to a major life threatening interaction when taken with Nintedanib
Lomitapide (Compound) resembles Fexofenadine (Compound) and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine